Zobrazeno 1 - 10
of 123
pro vyhledávání: '"Hassan Alin"'
Publikováno v:
Iranian Journal of Physics Research, Vol 23, Iss 1, Pp 115-124 (2023)
The most important nonlinear feature in the EEG response to external stimuli is the harmonic generation and entrainment which is due to the interaction between stimuli and ongoing brain oscillations. In this paper, we study the nonlinear brain dynami
Externí odkaz:
https://doaj.org/article/b4c94d7a77a6413dbb7604c43d1da0c9
Autor:
Hassan-Alin, M.1 mohammed.hassan-alin@astrazeneca.com, Naesdal, J.1, Nilsson-Pieschl, C.1, Långström, G.1, Andersson, T.2
Publikováno v:
Clinical Drug Investigation. 2005, Vol. 25 Issue 11, p731-740. 10p. 5 Charts, 4 Graphs.
Autor:
Mathias Liljeblad, T Andersson, B A Persson, Kerstin Röhss, Mohammed Hassan-Alin, Mohammad Niazi
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 44:119-127
Objective A combination of esomeprazole, amoxicillin and clarithromycin may be used for Helicobacter pylori eradication. We explored the potential for interactions between these drugs. Methods In 2 randomized, 4-way crossover studies, healthy CYP2C19
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b5473199576fb9350e8d1154874c920
https://doi.org/10.5414/cpp44119
https://doi.org/10.5414/cpp44119
Autor:
Tommy B. Andersson, Mohammed Hassan-Alin, Göran Långström, Jorgen Naesdal, Catharina Nilsson-Pieschl
Publikováno v:
Clinical Drug Investigation. 25:731-740
Background: We investigated the potential interactions between esomeprazole and a non-selective nonsteroidal anti-inflammatory drug (NSAID; naproxen) or a cyclo-oxygenase (COX)-2-selective NSAID (rofecoxib) in healthy subjects. Methods: Two studies o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ff71037f52edb6038d941780828c6c8
https://doi.org/10.2165/00044011-200525110-00006
https://doi.org/10.2165/00044011-200525110-00006
Autor:
Henrik Ahlbom, Kerstin Röhss, Catharina Nilsson-Pieschl, Mohammed Hassan-Alin, Christina Lundin, Clive H. Wilder-Smith, Patrik Bondarov, Mohammad Niazi
Publikováno v:
Clinical Drug Investigation. 25:517-525
Background: An intravenous (IV) formulation of esomeprazole has been developed as an alternative to oral administration. To meet the needs of different clinical situations it would be preferable if an IV dose could be administered as either an inject
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba7983a4cb1276509234e9fb788f6692
https://doi.org/10.2165/00044011-200525080-00004
https://doi.org/10.2165/00044011-200525080-00004
Publikováno v:
European Journal of Clinical Pharmacology. 60:779-784
To investigate the pharmacokinetics of S-omeprazole (esomeprazole), R-omeprazole and racemic omeprazole following single and repeated oral doses of 20 mg and 40 mg of each compound in healthy male and female subjects.In an open, randomised, three-way
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4d9f77075bffa0b8e8c0c2de55c1179
https://doi.org/10.1007/s00228-004-0841-1
https://doi.org/10.1007/s00228-004-0841-1
Publikováno v:
Alimentary Pharmacology & Therapeutics. 15:1563-1569
Background Esomeprazole, the S-isomer of omeprazole, is the first proton pump inhibitor developed as a single isomer for the treatment of acid-related diseases. Aim To examine the pharmacokinetics and pharmacodynamics of esomeprazole. Methods In a cr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1edb2c94caced00a74bc18ca7adff55a
https://doi.org/10.1046/j.1365-2036.2001.01087.x
https://doi.org/10.1046/j.1365-2036.2001.01087.x
Publikováno v:
Clinical Pharmacokinetics. 40:523-537
Esomeprazole, the (S)-isomer of omeprazole, is the first proton pump inhibitor (PPI) developed as a single isomer for the treatment of patients with acid related diseases. Because of the extensive use of PPIs, the documentation of the potential for d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce22d94e710c5e71ea09f7937bbb938a
https://doi.org/10.2165/00003088-200140070-00004
https://doi.org/10.2165/00003088-200140070-00004
Autor:
Tommy B. Andersson, Kerstin Röhss, Mohammed Hassan-Alin, Göran Hasselgren, Catharina Claar-Nilsson
Publikováno v:
Clinical Pharmacokinetics. 40:145-150
Esomeprazole is the first proton pump inhibitor to be developed as an optical isomer for the treatment of patients with acid-related diseases. The aim of this study was to examine the pharmacokinetics and tolerability of esomeprazole in the elderly,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f64e88b6c6796d344faa8b24ff97a0d9
https://doi.org/10.2165/00003088-200140020-00006
https://doi.org/10.2165/00003088-200140020-00006
Publikováno v:
Tropical Medicine & International Health. 2:461-467
Summary The activity of artemisinin in combination with mefloquine was tested in vitro against a chloroquine-sensitive (F32) strain of Plasmodium falciparum. A method of repetitive dosing and extending the culture observation period to 28–30 days w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f57f58059e72ddf0c95e5c53fa54c0af
https://doi.org/10.1111/j.1365-3156.1997.tb00168.x
https://doi.org/10.1111/j.1365-3156.1997.tb00168.x